Yunhee Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yunhee Choi has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Hee-Soo Kim
Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
2 shared publications - Hyunsook Hong
Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea
2 shared publications - Ji-Hyun Lee
Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
2 shared publications - Jung Min Chang
Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
2 shared publications - Myoung-Jin Jang
Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea
2 shared publications - Nariya Cho
Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea
2 shared publications
Latest Publications
- 25 April 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 199 (3) , 489-499
Use of imaging prediction model for omission of axillary surgery in early-stage breast cancer patients
Purpose To develop a prediction model incorporating clinicopathological information, US, and MRI to diagnose axillary lymph node (LN) metastasis with acceptable false negative rate (FNR) in patients with early stage, clinically node-negative breast cancers. Methods In this single center retrospective study, the inclusion criteria comprised women with clinical T1 or T2 and N0 breast cancers who underwent preoperative US and MRI between January 2017 and July 2018. Patients were temporally divided into the development and validation cohorts. Clinicopathological information, US, and MRI findings were collected. Two prediction models (US model and combined US and MRI model) were created using logistic regression analysis from the development cohort. FNRs of the two models were compared using the McNemar test. Results A total of 964 women comprised the development (603 women, 54 ± 11 years) and validation (361 women, 53 ± 10 years) cohorts with 107 (18%) and 77 (21%) axillary LN metastases in each cohort, respectively. The US model consisted of tumor size and morphology of LN on US. The combined US and MRI model consisted of asymmetry of LN number, long diameter of LN, tumor type, and multiplicity of breast cancers on MRI, in addition to tumor size and morphology of LN on US. The combined model showed significantly lower FNR than the US model in both development (5% vs. 32%, P < .001) and validation (9% vs. 35%, P < .001) cohorts. Conclusion Our prediction model combining US and MRI characteristics of index cancer and LN lowered FNR compared to using US alone, and could potentially lead to avoid unnecessary SLNB in early stage, clinically node-negative breast cancers.
- 25 April 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 199 (3) , 489-499
Use of imaging prediction model for omission of axillary surgery in early-stage breast cancer patients
Purpose To develop a prediction model incorporating clinicopathological information, US, and MRI to diagnose axillary lymph node (LN) metastasis with acceptable false negative rate (FNR) in patients with early stage, clinically node-negative breast cancers. Methods In this single center retrospective study, the inclusion criteria comprised women with clinical T1 or T2 and N0 breast cancers who underwent preoperative US and MRI between January 2017 and July 2018. Patients were temporally divided into the development and validation cohorts. Clinicopathological information, US, and MRI findings were collected. Two prediction models (US model and combined US and MRI model) were created using logistic regression analysis from the development cohort. FNRs of the two models were compared using the McNemar test. Results A total of 964 women comprised the development (603 women, 54 ± 11 years) and validation (361 women, 53 ± 10 years) cohorts with 107 (18%) and 77 (21%) axillary LN metastases in each cohort, respectively. The US model consisted of tumor size and morphology of LN on US. The combined US and MRI model consisted of asymmetry of LN number, long diameter of LN, tumor type, and multiplicity of breast cancers on MRI, in addition to tumor size and morphology of LN on US. The combined model showed significantly lower FNR than the US model in both development (5% vs. 32%, P < .001) and validation (9% vs. 35%, P < .001) cohorts. Conclusion Our prediction model combining US and MRI characteristics of index cancer and LN lowered FNR compared to using US alone, and could potentially lead to avoid unnecessary SLNB in early stage, clinically node-negative breast cancers.
- Open Access
- 30 September 2022
- Published by XMLink in Korean Journal of Radiology
- Vol. 23 (11) , 1067-1077
Sonazoid™ versus SonoVue® for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study
Kang HJ, et al. Korean J Radiol. 2022 Nov;23(11):1067-1077. https://doi.org/10.3348/kjr.2022.0388
- 30 September 2022
- Published by XMLink in Korean Journal of Radiology
- Vol. 23 (11) , 1067-1077
Open AccessSonazoid™ versus SonoVue® for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study
Kang HJ, et al. Korean J Radiol. 2022 Nov;23(11):1067-1077. https://doi.org/10.3348/kjr.2022.0388
- Open Access
- 17 March 2020
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 33 (7) , 676-684
Blood Pressure and Renal Progression in Patients Undergoing Percutaneous Coronary Intervention
BACKGROUND: High blood pressure (BP) may impair renal function following percutaneous coronary intervention (PCI). However, the predictability of renal progression based on admission and discharge BP and BP threshold values remains unclear.METHODS: A total of 8,176 adult patients who underwent PCI at Seoul National University Hospital from 2006 to 2016 were retrospectively analyzed. Renal progression was defined as a doubling of serum creatinine levels, ≥50% decrease of the estimated glomerular filtration rate, or development of end-stage renal disease. The risk of renal progression according to admission BP (any time) and discharge BP (8:00–10:00 am) was evaluated by multivariable Cox and additive generalized models with penalized splines.RESULTS: During a median follow-up of 7 years (maximum: 13 years), 9.3% of patients (n = 758) reached renal progression. BP between admission and discharge showed a low correlation, and all BP parameters showed a nonlinear relationship with renal progression. Systolic BP at discharge (SBPd) was selected as the best predictor of renal progression because the delta for the Akaike information criterion from the baseline model to the model with BP parameters was the lowest. The risk of renal progression started to increase at SBPd ≥ 125 mm Hg. This increasing risk of renal progression with SBPd ≥ 125 mm Hg remained significant, despite adjusting for the competing risk of all-cause death.CONCLUSIONS: High SBPd is associated with renal progression following PCI, particularly when it is ≥125 mm Hg. This can be used as a risk classification and potential target of renoprotective therapies.
- 17 March 2020
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 33 (7) , 676-684
Open AccessBlood Pressure and Renal Progression in Patients Undergoing Percutaneous Coronary Intervention
BACKGROUND: High blood pressure (BP) may impair renal function following percutaneous coronary intervention (PCI). However, the predictability of renal progression based on admission and discharge BP and BP threshold values remains unclear.METHODS: A total of 8,176 adult patients who underwent PCI at Seoul National University Hospital from 2006 to 2016 were retrospectively analyzed. Renal progression was defined as a doubling of serum creatinine levels, ≥50% decrease of the estimated glomerular filtration rate, or development of end-stage renal disease. The risk of renal progression according to admission BP (any time) and discharge BP (8:00–10:00 am) was evaluated by multivariable Cox and additive generalized models with penalized splines.RESULTS: During a median follow-up of 7 years (maximum: 13 years), 9.3% of patients (n = 758) reached renal progression. BP between admission and discharge showed a low correlation, and all BP parameters showed a nonlinear relationship with renal progression. Systolic BP at discharge (SBPd) was selected as the best predictor of renal progression because the delta for the Akaike information criterion from the baseline model to the model with BP parameters was the lowest. The risk of renal progression started to increase at SBPd ≥ 125 mm Hg. This increasing risk of renal progression with SBPd ≥ 125 mm Hg remained significant, despite adjusting for the competing risk of all-cause death.CONCLUSIONS: High SBPd is associated with renal progression following PCI, particularly when it is ≥125 mm Hg. This can be used as a risk classification and potential target of renoprotective therapies.
- Open Access
- 1 January 2020
- Published by XMLink in Korean Journal of Radiology
- Vol. 21 (5) , 561-571
Ultrafast Dynamic Contrast-Enhanced Breast MRI: Lesion Conspicuity and Size Assessment according to Background Parenchymal Enhancement
Kim SY, et al. Korean J Radiol. 2020 Feb;21:e52. https://doi.org/10.3348/kjr.2019.0567
- 1 January 2020
- Published by XMLink in Korean Journal of Radiology
- Vol. 21 (5) , 561-571
Open AccessUltrafast Dynamic Contrast-Enhanced Breast MRI: Lesion Conspicuity and Size Assessment according to Background Parenchymal Enhancement
Kim SY, et al. Korean J Radiol. 2020 Feb;21:e52. https://doi.org/10.3348/kjr.2019.0567
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Korean Medical Science
- Vol. 34 (28) , e192
The Author's Response: Evaluation of Propofol in Comparison with Other General Anesthetics for Surgery in Children Younger than 3 Years: a Systematic Review and Meta-Analysis
- 1 January 2019
- Published by XMLink in Journal of Korean Medical Science
- Vol. 34 (28) , e192
Open AccessThe Author's Response: Evaluation of Propofol in Comparison with Other General Anesthetics for Surgery in Children Younger than 3 Years: a Systematic Review and Meta-Analysis
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Korean Medical Science
- Vol. 34 (15) , e124
Evaluation of Propofol in Comparison with Other General Anesthetics for Surgery in Children Younger than 3 Years: a Systematic Review and Meta-Analysis
Hong H, et al. J Korean Med Sci. 2019 Apr;34(15):e124. https://doi.org/10.3346/jkms.2019.34.e124
- 1 January 2019
- Published by XMLink in Journal of Korean Medical Science
- Vol. 34 (15) , e124
Open AccessEvaluation of Propofol in Comparison with Other General Anesthetics for Surgery in Children Younger than 3 Years: a Systematic Review and Meta-Analysis
Hong H, et al. J Korean Med Sci. 2019 Apr;34(15):e124. https://doi.org/10.3346/jkms.2019.34.e124
- 4 August 2018
- Published by Springer Nature in Clinical Rheumatology
- Vol. 37 (10) , 2763-2770
Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis
To compare the preventive effect of tumor necrosis factor (TNF) inhibitors (anti-TNF antibody and soluble TNF receptor fusion protein (TNFR)) and nonsteroidal anti-inflammatory drugs (NSAIDs) on uveitis in patients with ankylosing spondylitis (AS). This retrospective cohort study included all AS patients (n = 1055) who have been treated with either TNF inhibitor or NSAIDs at the Seoul National University Hospital from 2004 to 2016. Treatment episodes of each patient were assigned to anti-TNF antibody (n = 517), TNFR (n = 341), and NSAID (n = 704) groups. The incidence of uveitis in each group was compared using a Cox proportional hazard model. The incidence rates of uveitis before and after initiation of TNF inhibitors were also assessed. A propensity score-matched (PSM) comparison was performed for a sensitivity analysis. Uveitis was significantly less common in the anti-TNF antibody group than the NSAID group (adjusted hazard ratio (HR) 0.53; 95% confidence interval (CI) 0.29–0.96) while it was higher in the TNFR group (adjusted HR 2.25, 95% CI 1.43–3.53). Anti-TNF antibody further reduced the incidence of uveitis when prescribed with NSAIDs (combination therapy) (adjusted HR 0.39; 95% CI 0.19–0.79). Combination therapy was preventive in AS patients with a history of uveitis (adjusted HR 0.31; 95% CI 0.12–0.81), but not in those without history of uveitis. The incidence rate of uveitis fell from 6.36 to 2.60 per 100 person-years when anti-TNF antibody was added to NSAIDs. Anti-TNF antibody plus NSAIDs reduces the risk of uveitis to a greater extent than NSAIDs alone in AS patients with a history of uveitis. Combination therapy may be an effective secondary prevention measure.
- 4 August 2018
- Published by Springer Nature in Clinical Rheumatology
- Vol. 37 (10) , 2763-2770
Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis
To compare the preventive effect of tumor necrosis factor (TNF) inhibitors (anti-TNF antibody and soluble TNF receptor fusion protein (TNFR)) and nonsteroidal anti-inflammatory drugs (NSAIDs) on uveitis in patients with ankylosing spondylitis (AS). This retrospective cohort study included all AS patients (n = 1055) who have been treated with either TNF inhibitor or NSAIDs at the Seoul National University Hospital from 2004 to 2016. Treatment episodes of each patient were assigned to anti-TNF antibody (n = 517), TNFR (n = 341), and NSAID (n = 704) groups. The incidence of uveitis in each group was compared using a Cox proportional hazard model. The incidence rates of uveitis before and after initiation of TNF inhibitors were also assessed. A propensity score-matched (PSM) comparison was performed for a sensitivity analysis. Uveitis was significantly less common in the anti-TNF antibody group than the NSAID group (adjusted hazard ratio (HR) 0.53; 95% confidence interval (CI) 0.29–0.96) while it was higher in the TNFR group (adjusted HR 2.25, 95% CI 1.43–3.53). Anti-TNF antibody further reduced the incidence of uveitis when prescribed with NSAIDs (combination therapy) (adjusted HR 0.39; 95% CI 0.19–0.79). Combination therapy was preventive in AS patients with a history of uveitis (adjusted HR 0.31; 95% CI 0.12–0.81), but not in those without history of uveitis. The incidence rate of uveitis fell from 6.36 to 2.60 per 100 person-years when anti-TNF antibody was added to NSAIDs. Anti-TNF antibody plus NSAIDs reduces the risk of uveitis to a greater extent than NSAIDs alone in AS patients with a history of uveitis. Combination therapy may be an effective secondary prevention measure.
- Open Access
- 1 June 2017
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 153 (6) , 529-536
Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma
Infantile hemangioma (IH) is the most common tumor of infants and young children.1,2 Although small IH lesions typically do not cause problems, they often require treatment because of the site of occurrence and associated complications such as abnormal eye development or vision problems, airway obstruction, and bowel obstruction.3,4 Historically, steroids have been used as the primary treatment for IH.5,6 Steroids have been shown to be antiangiogenic in a number of in vitro settings and also have shown good therapeutic effects clinically. However, the use of steroids may lead to various complications including gastroesophageal reflux and growth disorders, although these complications are associated with long-term use and high dose.7 A type of anticancer drug or immunomodulator, interferon alfa, may be used for severe IH in cases where patients did not respond to steroids.8,9 However, interferon alfa also has several possible adverse effects, including fever, muscle pain, systemic myalgia, and in severe cases, liver damage, blood toxic effects, thyroid hormonal abnormality, and neurological and neurodevelopmental toxic effects.8 Because of concerns about these adverse effects, many guardians of pediatric patients prefer to wait rather than accept treatment.
- 1 June 2017
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 153 (6) , 529-536
Open AccessComparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma
Infantile hemangioma (IH) is the most common tumor of infants and young children.1,2 Although small IH lesions typically do not cause problems, they often require treatment because of the site of occurrence and associated complications such as abnormal eye development or vision problems, airway obstruction, and bowel obstruction.3,4 Historically, steroids have been used as the primary treatment for IH.5,6 Steroids have been shown to be antiangiogenic in a number of in vitro settings and also have shown good therapeutic effects clinically. However, the use of steroids may lead to various complications including gastroesophageal reflux and growth disorders, although these complications are associated with long-term use and high dose.7 A type of anticancer drug or immunomodulator, interferon alfa, may be used for severe IH in cases where patients did not respond to steroids.8,9 However, interferon alfa also has several possible adverse effects, including fever, muscle pain, systemic myalgia, and in severe cases, liver damage, blood toxic effects, thyroid hormonal abnormality, and neurological and neurodevelopmental toxic effects.8 Because of concerns about these adverse effects, many guardians of pediatric patients prefer to wait rather than accept treatment.
- Open Access
- 3 September 2010
- Published by Wiley in BJU International
- Vol. 107 (9) , 1467-1472
Comparison of oncological outcomes of transperitoneal and retroperitoneal laparoscopic radical nephrectomy for the management of clear‐cell renal cell carcinoma: a multi‐institutional study
Study Type – Therapy (case series) Level of Evidence 4 What’s known on the subject? and What does the study add? Laparoscopic radical nephrectomy (LRN) can be performed by a retroperitoneal approach with similar efficacy compared to the transperitoneal approach. However, the oncological acceptance of LRN has been based on studies which have been carried out primarily by transperitoneal approach, and oncological results of the retroperitoneal approach alone are lacking. Our study confirmed that retroperitoneal laparoscopic radical nephrectomy is oncologically‐equivalent to transperitoneal approach in homogeneous group with the final pathological diagnosis of clear cell RCC. OBJECTIVE: To investigate the oncological efficacy of retroperitoneal laparoscopic radical nephrectomy (RLRN) compared with transperitoneal laparoscopic radical nephrectomy (TLRN) for the management of clear‐cell renal cell carcinoma (RCC). PATIENTS AND METHODS: With emphasis on survival and disease recurrence, a retrospective analysis was made of 580 patients who underwent TLRN (472 patients) or RLRN (108 patients) at 23 institutions between January 1997 and December 2007. Inclusion criteria were clear‐cell RCC, stage pT1 to pT2 without any nodal involvement, and metastasis. Overall survival and recurrence‐free survival curves were estimated using the Kaplan–Meier method. To assess the association between the surgical approach and survival outcomes, Cox proportional hazard models were constructed. RESULTS: The median follow‐up was 30 months in the TLRN group and 35.6 months in the RLRN group. Both groups were comparable regarding age, gender, body mass index (BMI), Fuhrman’s grade, size of tumours and stage. Kaplan–Meier curves and the log‐rank test showed no significant difference between the TLRN and RLRN groups in 5‐year overall (92.6% vs 94.5%; P = 0.669) and recurrence‐free survival (92.0% vs 96.2%; P = 0.244). In a Cox regression model with age, gender, Eastern Cooperative Oncology Group performance status, BMI, nuclear grade and T‐stage adjusted variables, no significant difference was found between the two surgical approaches. CONCLUSION: The present study is the largest oncological analysis for laparoscopic radical nephrectomy (LRN) comparing transperitoneal and retroperitoneal approaches. The data from it provide the objective evidence to suggest similar oncological outcomes for both approaches to LRN.
- 3 September 2010
- Published by Wiley in BJU International
- Vol. 107 (9) , 1467-1472
Open AccessComparison of oncological outcomes of transperitoneal and retroperitoneal laparoscopic radical nephrectomy for the management of clear‐cell renal cell carcinoma: a multi‐institutional study
Study Type – Therapy (case series) Level of Evidence 4 What’s known on the subject? and What does the study add? Laparoscopic radical nephrectomy (LRN) can be performed by a retroperitoneal approach with similar efficacy compared to the transperitoneal approach. However, the oncological acceptance of LRN has been based on studies which have been carried out primarily by transperitoneal approach, and oncological results of the retroperitoneal approach alone are lacking. Our study confirmed that retroperitoneal laparoscopic radical nephrectomy is oncologically‐equivalent to transperitoneal approach in homogeneous group with the final pathological diagnosis of clear cell RCC. OBJECTIVE: To investigate the oncological efficacy of retroperitoneal laparoscopic radical nephrectomy (RLRN) compared with transperitoneal laparoscopic radical nephrectomy (TLRN) for the management of clear‐cell renal cell carcinoma (RCC). PATIENTS AND METHODS: With emphasis on survival and disease recurrence, a retrospective analysis was made of 580 patients who underwent TLRN (472 patients) or RLRN (108 patients) at 23 institutions between January 1997 and December 2007. Inclusion criteria were clear‐cell RCC, stage pT1 to pT2 without any nodal involvement, and metastasis. Overall survival and recurrence‐free survival curves were estimated using the Kaplan–Meier method. To assess the association between the surgical approach and survival outcomes, Cox proportional hazard models were constructed. RESULTS: The median follow‐up was 30 months in the TLRN group and 35.6 months in the RLRN group. Both groups were comparable regarding age, gender, body mass index (BMI), Fuhrman’s grade, size of tumours and stage. Kaplan–Meier curves and the log‐rank test showed no significant difference between the TLRN and RLRN groups in 5‐year overall (92.6% vs 94.5%; P = 0.669) and recurrence‐free survival (92.0% vs 96.2%; P = 0.244). In a Cox regression model with age, gender, Eastern Cooperative Oncology Group performance status, BMI, nuclear grade and T‐stage adjusted variables, no significant difference was found between the two surgical approaches. CONCLUSION: The present study is the largest oncological analysis for laparoscopic radical nephrectomy (LRN) comparing transperitoneal and retroperitoneal approaches. The data from it provide the objective evidence to suggest similar oncological outcomes for both approaches to LRN.